James Scopa
QuietNamed in filings at MPM BioVentures
- Board seats filed
- 8
all filings on record
Named in filings at MPM BioVentures
all filings on record
last 24 months
from a verified or cited source
| Adverum Biotechnologies | Biotech & pharma | February 2024 | None on file |
| Aligos Therapeutics | Biotech & pharma | October 2023 | Versant Venture Capital, Vivo Innovation |
| DiCE MOLECULES HOLDINGS | Biotech & pharma | December 2020 | None on file |
| Blade Therapeutics | Biotech & pharma | June 2016 | None on file |
| Semma Therapeutics | Biotech & pharma | March 2015 | Aditum Bio |
| IDUN PHARMACEUTICALS | Biotech & pharma | February 2014 | Advent Life Sciences |
| Astute Medical | Biotech & pharma | January 2014 | Domain Partners |
| TriVascular Technologies | Biotech & pharma | February 2012 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name James Scopa on the board, based on 8 filed seats with a verified or cited source.